

# sharon Alroy Preis

Disclosure Purpose: 21-09730

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Acute Inflammatory Myocarditis Following Pfizer-BioNTech Vaccine BNT162b2 for COVID-19 During a Nationwide Immunization Campaign in Israel.

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

D. Mevorach<sup>1\*</sup>, MD, E. Anis<sup>2,3\*</sup>, MD, N. Cedar<sup>2#</sup>, MPH, M. Bromberg<sup>4#</sup>, MD., E J. Haas<sup>2,5</sup>, MD, E. Nadir<sup>2</sup>, MD, S. Olsha-Castel<sup>5</sup>, MD, D. Arad<sup>5</sup>, RN, BA, MSN, R. Dichtiar<sup>4</sup>, MPH., D. Novik<sup>4</sup>; MPH, Y. Hershkovitz<sup>4</sup>, MPH., T. Hasin<sup>6</sup>, MD, N. Levy<sup>6</sup>, MD, R. Asleah<sup>1</sup>, MD, O. Amir<sup>1</sup>, MD, K. Meir<sup>1</sup>, MD, D. Cohen<sup>1</sup>, MD, R. Dagan<sup>5</sup>, MD, I. Leidesdorff<sup>7</sup>, MD, R. Ben-Ami<sup>8</sup>, MD, I Miskin<sup>1,9</sup>, MD, W. Saliba<sup>10</sup>, MD, K. Muhsen<sup>11</sup>, PhD., Y. Levy<sup>7</sup>, MD, M.S. Green<sup>12</sup>, MD, PhD., L. Keinan-Boker<sup>4,12\*</sup>, MD, PhD., S. Alroy-Preis<sup>7\*</sup>, MD, MPH.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-09730

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Other	Self
<i>Category:</i> Other <i>Additional Information:</i> As director of cardiology departments in Poriya Medical Center (2014-2019) and Hadassah Medical Center Israel (2019- now) , my departments participated and was paid for its participation in clinical trials of Pfizer		<i>Description:</i> I got a research grant from Pfizer. I served as investigator in clinical trials of Pfizer
Pfizer	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Honorariums for lectures-Pfizer Advisory board-Pfizer

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  
No.
- What is the manuscript title?  
Epidemiology of Myocarditis After the BNT162b2 COVID-19 Vaccine in Israel
- Are you the corresponding author?  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Acute Inflammatory Myocarditis Following Pfizer-BioNTech Vaccine BNT162b2 for COVID-19 During a Nationwide Immunization Campaign in Israel
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. What is the manuscript title?**  
Epidemiology of Myocarditis after the BNT 162BT Covid 19 in Israel
- 3. Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Epidemiology of Myocarditis After the BNT162b2 COVID-19 Vaccine in Israel
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-09730

Summary of Interests

**Company or Organization**

Entity	Type	Interest Held By
<a href="#">Gilead Sciences</a>	Consultant	Self
<i>Category: Consultant</i> <i>Additional Information:</i>		<i>Description:</i>
<a href="#">Merck</a>	Consultant	Self
<i>Category: Consultant</i> <i>Additional Information:</i>		<i>Description:</i>
<a href="#">Pfizer Inc.</a>	Consultant	Self
<i>Category: Consultant</i> <i>Additional Information:</i>		<i>Description:</i>
<a href="#">Teva Pharmaceutical Industries</a>	Consultant	Self
<i>Category: Consultant</i> <i>Additional Information:</i>		<i>Description:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Myocarditis After BNT162b2 COVID-19 Vaccine in the Israeli Ministry of Health Database
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-09730

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Myocarditis After BNT162b2 COVID-19 Vaccine in the Israeli Ministry of Health Database
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Epidemiology of Myocarditis After the BNT162b2 COVID-19 Vaccine in Israel
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.





**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Epidemiology of Myocarditis After the BNT162b2 COVID-19 Vaccine in Israel
- Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-09730

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
<b>MedImmune</b>	Grant / Contract	Other - Ben-Gurion University of the Negev
<i>Recipient Name:</i> Ben-Gurion University of the Negev <i>Grant / Contract Description:</i> <i>Additional Information:</i> Principal investigator		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
<b>Merck Sharp and Dohme</b>	Grant / Contract	Other - Ben-Gurion University of the Negev
<i>Recipient Name:</i> Ben-Gurion University of the Negev <i>Grant / Contract Description:</i> <i>Additional Information:</i> Principal investigator		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
<b>Merck Sharp and Dohme</b>	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Scientific consultant; Advisory board; speaker
<b>Pfizer</b>	Grant / Contract	Other - Ben-Gurion University of the Negev
<i>Recipient Name:</i> Ben-Gurion University of the Negev <i>Grant / Contract Description:</i> <i>Additional Information:</i> Principal investigator		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
<b>Pfizer</b>	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Scientific consultant; advisory committee; speaker
<b>SANOFI PASTEUR INC.</b>	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Speaker

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  
No.
- What is the manuscript title?  
Epidemiology of Myocarditis After the BNT162b2 COVID-19 Vaccine in Israel
- Are you the corresponding author?  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Epidemiology of Myocarditis After the BNT162b2 COVID-19 Vaccine in Israel
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-09730

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Myocarditis After BNT162b2 COVID-19 Vaccine in the Israeli Ministry of Health Database
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Epidemiology of myocarditis after the BNT162b2 vaccine in Israel
- Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Myocarditis After BNT162b2 COVID-19 Vaccine in the Israeli Ministry of Health Database
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Epidemiology of Myocarditis After the BNT162b2 COVID-19 Vaccine in Israel
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-09730

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
"Acute Inflammatory Myocarditis Following Pfizer-BioNTech Vaccine BNT162b2 for COVID-19 During a Nationwide Immunization Campaign in Israel"
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.





**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Myocarditis After BNT162b2 COVID-19 Vaccine in the Israeli Ministry of Health Database
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-09730

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Myocarditis After BNT162b2 COVID-19 Vaccine in the Israeli Ministry of Health Database
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
21-09730: myocarditis after BNT162b2 COVID19 vaccine un the Israeli ministry of health database
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Myocarditis After BNT162b2 COVID-19 Vaccine in the Israeli Ministry of Health Database
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-09730

## Summary of Interests

**Company or Organization**

Entity	Type	Interest Held By
<a href="#">Enlivex Therapeutics</a>	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> 10 weekly hours		<i>Description:</i> Chief scientific officer and founder

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Myocarditis After BNT162b2 COVID-19 Vaccine in the Israeli Ministry of Health Database
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-09730

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Epidemiology of Myocarditis After the BNT 162b2 COVID-19 Vaccine in Israel
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Epidemiology of Myocarditis After the BNT162b2 COVID-19 Vaccine in Israel
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Epidemiology of Myocarditis After the BNT162b2 COVID-19 Vaccine in Israel
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.





**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Myocarditis After BNT162b2 COVID-19 Vaccine in the Israeli Ministry of Health Database
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-09730

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Myocarditis after BNT162b2 covid-19 vaccine in the Israeli ministry of health database
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-09730

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Epidemiology of Myocarditis After the BNT162b2 COVID-19 Vaccine in Israel
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.

